Increased Potency of a Bi-specific TL1A-ADAM17 (TACE) Inhibitor by Cell Surface Targeting-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Increased Potency of a Bi-specific TL1A-ADAM17 (TACE) Inhibitor by Cell Surface Targeting

Published:2017-08-22 Issue: Volume:4 Page:
ISSN:2296-889X
Container-title:Frontiers in Molecular Biosciences
language:
Short-container-title:Front. Mol. Biosci.

Author:

Weizman Tomer,Levin Itay,Zaretsky Marianna,Sagi Irit,Aharoni Amir

Funder

Israel Science Foundation

Publisher

Frontiers Media SA

Subject

Biochemistry, Genetics and Molecular Biology (miscellaneous),Molecular Biology,Biochemistry

Reference31 articles.

1. Inflammatory bowel disease;Abraham;N. Engl. J. Med.,2009

2. ADAM17 as a therapeutic target in multiple diseases;Arribas;Curr. Pharm. Des.,2009

3. Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease;Bamias;J. Immunol.,2003

4. Role of TL1A and its receptor DR3 in two models of chronic murine ileitis;Bamias;Proc. Natl. Acad. Sci. U.S.A.,2006

5. Role of ADAM17 in the ectodomain shedding of TNF-alpha and its receptors by neutrophils and macrophages;Bell;J. Leukoc. Biol.,2007

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TL1A inhibition for inflammatory bowel disease treatment: From inflammation to fibrosis;Med;2024-05

2. Developing a dual VEGF/PDL1 inhibitor based on high-affinity scFv heterodimers as an anti-cancer therapeutic strategy;Scientific Reports;2023-07-24

3. Developing a Dual VEGF/PDL1 Inhibitor Based on High-Affinity scFv Heterodimers as an Anti- cancer Therapeutic Strategy;2023-04-17

4. A combinational approach to restore cytokine balance and to inhibit virus growth may promote patient recovery in severe COVID-19 cases;Cytokine;2020-12

5. TL1A–DR3 Plasma Levels Are Predictive of HIV-1 Disease Control, and DR3 Costimulation Boosts HIV-1–Specific T Cell Responses;The Journal of Immunology;2020-11-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3